Clinical Trials Browser

Phase 2 × NIH × GSK2141795 × Clear all

NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

Phase 2 Active not recruiting

42 enrolled 13 charts

Uveal Melanoma

NCT01989598 2022-03-02

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

25 enrolled 11 charts

Multiple Myeloma

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

37 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01907815 2018-04-06

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Phase 2 Terminated

24 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute